Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has raised the first $45 million of a series B round that could reach $60 million -- although the COVID-19 outbreak could affect the company’s timeline for a final close.

New investors GV, Bill Gates and Foresite Capital led the round. Also participating were Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;

Read the full 639 word article

How to gain access

Continue reading with a
two-week free trial.